Drug Profile


Alternative Names: BCDF; Interferon-beta-2; interferon-β - 2; rhIL-6; β - 2 IF

Latest Information Update: 07 Oct 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cangene Corporation
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Interleukin stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bacterial infections; Chemotherapy-induced damage; Thrombocytopenia

Most Recent Events

  • 07 Oct 2002 Discontinued - Phase-I for Chemotherapy induced damage in France and Switzerland (SC)
  • 07 Oct 2002 Discontinued - Phase-I for Thrombocytopenia (Chemotherapy-induced) in France and Switzerland (SC)
  • 07 Oct 2002 Discontinued - Preclinical for Bacterial infections in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top